Side effects

Visceral adipose tissue returns to baseline after stopping therapeutic intervention with rHGH

Raltegravir body composition study: 48-week DEXA results

Lipid and metabolic changes with ARV combinations

Tenofovir and renal safety

Assessing the cardiovascular impact of HIV, abacavir, and new signals for lopinavir/r

Intensive smoking cessation programme reports limited success at 6 months

HDL particle concentration predicts cardiovascular disease in SMART

CD4 count >250 not predictive of rash-associated hepatoxicity among women initiating nevirapine-based ART in Zambia, Thailand, and Kenya

Genetic markers linked to early discontinuation of three antiretrovirals

High rate of rash in HIV negative volunteers combining raltegravir and darunavir

Bone loss in SMART study

Parathyroid hormone and vitamin D levels in patients using tenofovir

Haemoglobin A1c (HbA1c) may underestimate glycaemia in patients with diabetes on HIV therapy

Statin use in HIV-positive patients

Abacavir and heart disease: SMART study supports an abacavir-associated increased risk of cardiovascular disease

EMEA state that animal studies support no increased risk of malignancy from contamination of nelfinavir (Viracept) with ethyl mesilate (EMS)

Ritonavir label updated in the US relating to cardiac arrhythmia reported in high-dose studies

Bone problems raised in several UK studies

New-fill used to treat lipoatropy in feet

Tesamorelin (TH9507) reduces abdominal fat in patients with HIV-related lipodystrophy: 52 week results

Case report of efavirenz-associated nephrolithiasis

Yellow card reporting scheme for doctors and patients in the UK

30 cases of atazanavir-related kidney stones reported

Tenofovir and indinavir associated with increased risk of chronic renal failure in EuroSIDA study

Growth hormone release factor (TH9507) reduces central fat adiposity

Further insight into risk and management of cardiovascular disease (CVD) from D:A:D cohort: no additional benefit of metabolic syndrome diagnosis; new HIV-specific CVD risk equations; increasing uptake of lipid lowering drugs but low smoking cessation

d4T associated with significantly increased risk of type-2 diabetes mellitus

Switching from PIs to NNRTIs has similar effect on TC/HDL ratio as use of lipid lowering drugs in the management of dyslipidaemia

The role of the metabolic syndrome in HIV

Effect of lifestyle modification on risk factors for cardiovascular disease and metabolic syndrome

Pioglitazone reduces peripheral lipoatrophy and improves adipokines without reducing visceral fat

Tenofovir did not increase the incidence nephrotoxicity in limited numbers of HIV-positive patients using chemotherapy or HCV-coinfeced patients using ribavirin

Use of HLA-B*5701 genetic testing to reduce abacavir hypersensitivity reactions

Regimen durability and toxicity in 36-month follow up on ART in Khayelitsha, South Africa

D:A:D study shows that PIs rather than NNRTIs drive the previously reported cardiovascular risk of combination antiretroviral therapy

Interventions for the management of lipodystrophy and metabolic complications

Analysis of hepatic events in 2NN study by CD4 entry criteria, levels differences between nevirapine and efavirenz; excess hepatic events in once-daily nevirapine arm linked to single site in Thailand

Factors associated with sexual dysfunction in HIV patients

African-Americans in ACTG 5095 had shorter time to virologic failure and grade 3/4 side effects

Predictors of insulin resistance in first year of therapy

Monitoring side effects in resource limited countries

Uridine supplement reverses thymidine-induced lipoatrophy

Pravastatin increases limb fat in HIV-positive patients with hypercholesterolaemia

Evidence that facial fat can return after switching from either d4T or AZT, to abacavir or tenofovir

Niacin has beneficial effect on lipids but no reduction in abdominal fat

Gluteal implants used to replace lost buttock fat

Fatigue among HIV-positive patients in the era of highly active antiretroviral therapy

EMEA statement on metabolic and cardiovascular complications of antiretroviral therapy in HIV-infected patients

EMEA statement on use of antiretroviral treatment in HIV-patients with hepatic impairment and/or HBV/HCV co-infection

Levels of efavirenz 10-fold above minimum target level despite coadministration with rifampicin

Absolute risk is modest, but cumulative cardiovascular risk of HAART over five years is similar to ‘ever smoked’: new data on gender and age

Omega-3 supplement effective to reduce triglycerides

Switch to tenofovir from AZT or d4T improves fat loss and improves lipid parameters compared to abacavir

Continued use of a thymidine analogue may limit benefit from rosiglitazone when used to treat lipoatrophy

EuroSIDA shows HIV-HCV coinfected patients more likely to stop HAART because of side effects

Nucleoside analogue-related mitochondrial toxicity and link to lipoatrophy: effect of non-thymidine analogues abacavir and tenofovir

Potential for uridine to treat mitochondrial toxicity: still only in vitro data

rHGH reduces central fat accumulation in adolescent lipodystrophy

Endothelial dysfunction similar in ARV-experienced and -naive patients

Pravastatin improves lipid profiles but not endothelial function

Treatment interruptions improve lipids within four weeks: IL-2 has no metabolic effect

Improvement of lipids following switch to tenofovir

Restorative treatments for HIV-associated lipoatrophy

Side effects update: hypersensitivity, heart, bones

Vancouver researchers urge caution with combinations of lipid drugs

Post navigation